Liquidia Q2 2024 Earnings Report
Key Takeaways
Liquidia Corporation reported revenue of $3.7 million and a net loss of $27.9 million for the second quarter ended June 30, 2024. The company's cash and cash equivalents totaled $133.1 million as of June 30, 2024.
Judge Andrews denied the motion for preliminary injunction filed by United Therapeutics (UTHR) in its lawsuit alleging that YUTREPIA infringes U.S. Patent No. 11,826,327 (‘327 patent).
The U.S. District Court for the District of Columbia has denied motions for a temporary restraining order and preliminary injunction requested by UTHR in its suit against the U.S. Food and Drug Administration (FDA).
Liquidia presented two live thematic poster sessions and five encore presentations covering the company’s investigational products, YUTREPIA™ (treprostinil) inhalation powder and L606 (liposomal treprostinil) inhalation suspension at the World Symposia on Pulmonary Hypertension.
Liquidia presented data related to the investigational use of L606 (liposomal treprostinil) inhalation suspension in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) at the ATS Conference in San Diego.